Two recent articles shed some light on how the market for reproductive healthcare is evolving.
Dr. Jessica Chen writes "I dispensed mifepristone every day in the clinic last week, and not once was it for abortion." Instead it was to help patients who had suffered a miscarriage, and were still carrying a dead fetus.
The US is expecting legal wrangling over whether mifepristone can be prescribed by telehealth providers, to women in states that forbid abortion. Some of the arguments may depend on whether it is an "abortion pill," or a drug with multiple uses in reproductive healthcare.
The Clinical Indications for Mifepristone Go Beyond Abortion Jessica Chen, MD, JAMA
Published Online: August 28, 2025 doi: 10.1001/jama.2025.13376
#############
Considering Telehealth Across State Lines in Uncertain Times, by Nicole Huberfeld, JD1; Katharine O. White, MD, MPH2; Rachel Cannon, MD, MSc2, JAMA Published Online: August 11, 2025 doi: 10.1001/jama.2025.12122
"Since the US Supreme Court decided in 2022 that abortion was no longer protected as part of the constitutional right to privacy, state lawmakers have been empowered by the court leaving abortion policy “to the people and their elected representatives.”1 This phrase has fostered deep conflicts between state laws relating to abortion and laws relating to other health care for people of reproductive age, and it has created new risks for physicians who provide care to patients across state lines."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.